NCT00971633View on ClinicalTrials.gov

A Bioequivalence Study of 3 Formulations of Ondansetron in Healthy Adults (0869-095)(COMPLETED)

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

November 30, 2003

Primary Completion Date

December 31, 2003

Study Completion Date

January 31, 2004

Conditions
Chemotherapy-Induced Nausea and Vomiting
Interventions
DRUG

Comparator: Treatment A (Zofran, ondansetron)

an over-encapsulated single 8 mg tablet of United Kingdom (U.K.) Zofran taken by mouth (PO)

DRUG

Comparator: Treatment B (Zofran, ondansetron)

a single 8 mg tablet of Zofran marketed in the U.K., taken PO

DRUG

Comparator: Treatment C (Zofran, ondansetron)

a single 8 mg tablet of Zofran marketed in the United States (U.S.), taken PO

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00971633 - A Bioequivalence Study of 3 Formulations of Ondansetron in Healthy Adults (0869-095)(COMPLETED) | Biotech Hunter | Biotech Hunter